Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:1 September 2023

This phase I/II trial is testing how safe and tolerable a new targeted cancer therapy is for the treatment of patients with mature B-cell blood cancer (when given in combination with the standard targeted therapy, zanubrutinib) or for patients with a type of advanced cancer (given in combination with the standard targeted therapy, tislelizumab)A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3KÎ´) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible patients will be assigned to receive BGB-10188: as monotherapy in participants with mature B-cell malignancies; in combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.

Age

People 18+

Phase

I/II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04282018
BGB-A317-3111-10188-101

Commercial Sponsor

BeiGene Australia Pty Ltd

Scientific Title

A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3KÎ´) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Closed hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy